ストックスクリーナーアプリを入手
98.58
1.86%
1.80
Palvella Therapeutics Inc (PVLA) 最新ニュース
Is Longfor Group Holdings Limited RLF a good long term investmentFederal Reserve Announcements & Small Investment Big Gains - earlytimes.in
Palvella Therapeutics stock maintains Buy rating at H.C. Wainwright By Investing.com - Investing.com Canada
Palvella Therapeutics (PVLA) price target increased by 15.61% to 133.70 - MSN
XTX Topco Ltd Acquires Shares of 17,701 Palvella Therapeutics, Inc. $PVLA - MarketBeat
Palvella Therapeutics Secures New U.S. Patent for QTORIN Rapamycin - MSN
Palvella Therapeutics initiated with a buy at Craig-Hallum - MSN
Palvella Therapeutics (NASDAQ:PVLA) Trading 8% HigherStill a Buy? - MarketBeat
Palvella Therapeutics to Announce Q1 2025 Financial Results and Host Investor Call - MSN
Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Analysts at Craig Hallum - MarketBeat
Palvella Therapeutics (PVLA) Price Target Increased by 15.61% to 133.70 - Nasdaq
Analysts Are Bullish on Top Healthcare Stocks: Adicet Bio (ACET), Palvella Therapeutics (PVLA) - The Globe and Mail
Clear Street Initiates Coverage of Palvella Therapeutics (PVLA) with Buy Recommendation - Nasdaq
BTIG Initiates Coverage of Palvella Therapeutics (PVLA) with Buy Recommendation - Nasdaq
Clear Street Initiates Coverage on PVLA with a 'Buy' Rating | PV - GuruFocus
This Oklo Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday - Benzinga
BTIG Initiates Palvella Therapeutics With Buy Rating, $167 Price Target - marketscreener.com
BTIG initiates coverage on Palvella Therapeutics stock with Buy rating By Investing.com - Investing.com Canada
Craig-Hallum Initiates Coverage of Palvella Therapeutics (PVLA) with Buy Recommendation - Nasdaq
Clear Street initiates Palvella Therapeutics stock with Buy rating, $200 target - Investing.com Canada
Will Palvella Therapeutics Inc. (PI6) stock beat revenue estimates2025 Price Targets & Long-Term Investment Growth Plans - Newser
How Palvella Therapeutics Inc. (PI6) stock compares with top peersJuly 2025 Reactions & Safe Capital Preservation Plans - Newser
Lymphatic Malformations Market Expected to Experience Major - openPR.com
Can Palvella Therapeutics Inc. stock sustain revenue growth2025 Volatility Report & Risk Managed Investment Signals - Newser
Palvella Therapeutics (NASDAQ:PVLA) Sees Strong Trading VolumeTime to Buy? - MarketBeat
Will Palvella Therapeutics Inc. (PI6) stock keep high P E multiplesMarket Growth Summary & Risk Managed Trade Strategies - Newser
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives $117.33 Consensus PT from Brokerages - Defense World
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Down 7.9%Should You Sell? - MarketBeat
Tech Rally: How risky is Palvella Therapeutics Inc stock now2025 Geopolitical Influence & Technical Entry and Exit Tips - BỘ NỘI VỤ
Palvella Therapeutics (PVLA) Stock Analysis Report | Financials & Insights - Benzinga
Will Palvella Therapeutics Inc. stock benefit from automationJuly 2025 Rallies & High Yield Stock Recommendations - Newser
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Tiny Biotech’s Big Bet On Rare Skin Diseases - Finimize
Will Palvella Therapeutics Inc. stock continue upward momentumJuly 2025 Market Mood & Weekly Consistent Profit Watchlists - BỘ NỘI VỤ
Palvella Therapeutics stock hits 52-week high at 104.99 USD By Investing.com - Investing.com Australia
Palvella Therapeutics stock hits 52-week high at 104.99 USD - Investing.com India
Palvella Therapeutics, Inc. $PVLA Stake Reduced by Adams Street Partners LLC - MarketBeat
Can Palvella Therapeutics Inc. (PI6) stock survive global slowdownMarket Volume Report & Free Real-Time Market Sentiment Alerts - moha.gov.vn
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sagimet Biosciences, Inc. Class A (SGMT), Bristol-Myers Squibb (BMY) and Palvella Therapeutics (PVLA) - The Globe and Mail
Ready to Jump After Recent Trade: Palvella Therapeutics Inc (PVLA) - setenews.com
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Up 7.9%Should You Buy? - MarketBeat
Stifel Maintains Palvella Therapeutics (PVLA) Buy Recommendation - Nasdaq
The Short-Sellers May Be Right About This Red-Hot Pharma Stock - Yahoo Finance
Palvella Therapeutics stock price target raised to $145 by Stifel - Investing.com Canada
Insider Selling: Palvella Therapeutics (NASDAQ:PVLA) COO Sells 4,302 Shares of Stock - MarketBeat
Palvella Therapeutics COO Kathleen Goin Sells All Directly Owned Common Stock - TradingView
Is Frog Cellsat Limited Positioned to Benefit From Secular ShiftsCandlestick Trading Patterns & Discover Your Financial Freedom Formula - earlytimes.in
Palvella Therapeutics stock hits 52-week high at $98.60 By Investing.com - Investing.com Canada
Will Palvella Therapeutics Inc. (PI6) stock rise with strong economyQuarterly Portfolio Report & Stepwise Trade Signal Implementation - newser.com
Palvella Therapeutics (NASDAQ:PVLA) Shares Gap Up Following Analyst Upgrade - Defense World
Palvella Therapeutics (NASDAQ:PVLA) Stock Rating Upgraded by Raymond James Financial - Defense World
Palvella Therapeutics stock hits 52-week high at $98.60 - Investing.com India
Palvella Therapeutics Inc (PVLA) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Setenews
Why Palvella Therapeutics Inc. stock remains a top recommendationRecession Risk & Low Drawdown Investment Ideas - newser.com
First Light Asset Management, LLC's Palvella Therapeutics Inc(PVLA) Holding History - GuruFocus
Will Palvella Therapeutics Inc. stock continue dividend increasesWeekly Earnings Recap & Risk Adjusted Buy/Sell Alerts - newser.com
1.08%
0.91%
大文字化:
|
ボリューム (24 時間):